Drug Profile

Octreotide long acting injection - Consegna Pharma

Alternative Names: CP-107 - Consegna Pharma

Latest Information Update: 30 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Consegna Pharma
Class Alcohols; Amides; Amines; Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

28 Apr 2026 Octreotide is available for licensing as of 28 Apr 2026. https://www.consegnapharma.com/pipeline (Consegna Pharma webiste, April 2026)
28 Apr 2026 Chemical structure information added
28 Apr 2026 Investigation in Cancer in USA (Parenteral), before April 2026 (Consegna Pharma pipeline, April 2026)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com